From the first launch to ongoing market access operational execution, IntegriChain solves some of the most complex and pressing challenges associated with drug commercialization. We deliver pharma’s only comprehensive data, consulting, and business process platform for market access departments, providing the strategy, data, applications, and infrastructure for therapy commercialization.
Solutions overview
IntegriChain delivers the pharmaceutical industry’s largest and only data and business process platform for therapy commercialization and access. Manufacturers rely on our analytics, applications, and managed services to power their operations and harness the value of their channel, patient and payer data.
View all products
IntegriChain provides a complete set of professional services for commercialization and market access execution–from life science strategy and operational consulting to implementation, integration, migrations, and analytics.
Services overview
We help all stakeholders in the pharmaceutical industry drive access with our relentless focus on unifying all of the critical business functions for therapy commercialization and access – contracts & pricing, gross-to-net, channel, and patient services – to unlock strategic payer, provider, pharmacy and patient access insights.
Learn more about our company
Learn more about joining our growing IntegriChain team of data scientists, market access experts, analysts, and consulting professionals – our culture, our purpose, our teams in the US and Pune. Check out our careers or keep in touch for future opportunities.
Careers overview
Our pharmaceutical data aggregation and refinement solutions unite data sets from sales, inventory, specialty pharmacy inventory, and product returns channels while leveraging industry-leading data science and enrichment algorithms to deliver an end-to-end view of your distribution.
Streamline and enhance the reliability, accuracy, and usage of critical EDI and non-EDI channel datasets by leveraging IntegriChain’s ICyte Platform to collect, steward, and master critical 852, 867, 180, 850 and ExFactory data across:
Makes it easy to pass data throughout all supply chain channels. ICyte channel data aggregation helps make sense of the multiple data sets and transforms them into accurate, timely inventory insight.
The ICyte Platform directly connects to pharmaceutical wholesalers and processes wholesale EDI and flat files through AS2 and SFTP. ICyte supports the direct processing of EDI 852, EDI 867, Chargebacks, and manufacturer’s Ex-factory data from wholesalers and specialty pharmacies, manufacturers, and third-party logistics (3PL) providers.
IntegriChain works with you to establish a channel data aggregation and review schedule for relevant data sets being transmitted. Within the schedule, IntegriChain tracks the time and dates on which each data set is to be reported and the required reporting fields.
IntegriChain assigns a data quality analyst to each customer. The data quality analyst monitors data timeliness, completeness, and accuracy exceptions. They will then escalate any detected exceptions to specified customer contacts by close of the business day on which the exception is detected
Leverage industry-leading channel data science to improve your visibility downstream. Despite the increased cost of distribution service fees, there remains extensive data redaction in indirect sales reporting (e.g. 867) provided to manufacturers. The degree to which data is either partially blinded (fields identifying the downstream customer) or fully blinded (entire records identifying customer sales or returns are omitted) depends on your brand’s archetype. For example, primary care brands sold primarily in national pharmacy chains may be redacted 50% or more. Although specialty drugs typically have less blinding and blocking, the percentage is increasing even as specialty distribution fees are growing.
Implications of Data Visibility Gaps:
Since 2008, IntegriChain has pioneered 867 data unblinding and unblocking, and the creation of analytics to address the industry challenges discussed above. We can identify the ship-to location and then cross-reference to Ship-To Parent Accounts, Bill-To Parent Accounts, nine channels and 95 classes of trade.
Each data provider’s unique layouts are mapped to IntegriChain’s integrated data model. Data is then scrubbed for key quality checks such as missing data, duplicate data, or invalid records. All pharmaceutical data is aligned to a common product master and trade partner master that are maintained by IntegriChain data analysts. The product master ensures that consistent naming and unit of measure standards are used across all channel data. In the ICyte Platform, manufacturer trade and channel teams can view and report their channel data in extended units, pack units, today’s current WAC price, historic WAC price, or molecular units. All datasets are cleansed and mastered against IntegriChain’s Point of Care Outlet Master which includes a channel and class-of-trade schema including 750k+ gold customer account records, 500k+ gold product records, and 10,000+ parent hierarchies.
The ICyte Platform includes a powerful embedded business intelligence tool that offers advanced visualization techniques, interactive dashboards, robust data extractions, and rich ad hoc capabilities built on the industry-leading Spotfire tool. The solution features more than 20 reports, dashboards, and pre-configured analytics to analyze days on hand, trade partner omissions, inventory roll-forwards, ExFactory sales, returns, indirect sales, and other reports critical to trade account management, operations, and the finance organization.
Discover More About Channel Solutions
Learn how a fast-growing manufacturer of precision medicines leveraged a unified patient and channel data solution to realize improved channel performance and create a common platform for all future launches, regardless of network design or complexity.
Download the Case Study
Insights into specialty lite challenges and a new pharmaceutical distribution channel strategy that has emerged to help manufacturers balance patient access with their gross-to-net
Read the Blog
